Skip to main
INVA
INVA logo

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva Inc has demonstrated strong financial performance with significant year-over-year sales growth since its acquisitions, particularly noting a 33% increase in sales for Giapreza from 2023 to 2024. Xerava, another key product, has maintained an impressive annual sales growth rate of over 20%, highlighting the success of the company's strategic portfolio management. Overall, since acquiring these assets in the third quarter of 2022, annualized run rates for both Giapreza and Xerava have nearly doubled, indicating robust market demand and effective integration within Innoviva’s operations.

Bears say

Innoviva Inc. faces a challenging financial outlook, primarily due to projected average year-over-year declines in royalties from GSK for its key products, Relvar/Breo and Anoro, estimated at -8% and -4% respectively over the next eight years. The company's revenue trajectory is further complicated by the anticipated loss of exclusivity for Giapreza in 2034, which may significantly impact future income streams. Additionally, concerns regarding the efficacy and limited use of colistin against multi-drug-resistant strains may further jeopardize the company's performance within its critical care and infectious disease operating assets.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.